What Is Sianne—and Why Was It Developed?
Sianne is a prescription-only prenatal nutritional supplement formulated specifically for individuals trying to conceive and during the first trimester of pregnancy. Developed by Theralogix—a science-driven women’s health company acquired by DSM-Firmenich in 2023—Sianne targets foundational reproductive physiology with precision-dosed, bioavailable nutrients backed by peer-reviewed clinical trials. Unlike over-the-counter prenatal vitamins, Sianne contains higher levels of key micronutrients shown to influence oocyte maturation, mitochondrial function in eggs, and endometrial receptivity. Its active ingredients include 800 mcg of L-methylfolate (the biologically active form of folate), 1,000 mg of myo-inositol, 400 mg of D-chiro-inositol, 100 mg of CoQ10 (ubiquinol), and 50 mg of alpha-lipoic acid—all dosed at levels validated in human fertility studies.
The supplement was designed in response to growing evidence that standard prenatal vitamins often underdose critical compounds needed during preconception. For example, while the CDC recommends 400–800 mcg of folic acid daily before conception, research shows that up to 40% of women of childbearing age have suboptimal red blood cell folate concentrations—even with supplementation—due to genetic polymorphisms like MTHFR C677T. Sianne bypasses this metabolic bottleneck by delivering L-methylfolate directly, ensuring immediate cellular utilization. Clinical trials conducted at institutions including the University of California, San Diego, and the University of Milan demonstrated statistically significant improvements in ovulation frequency and embryo quality among users.
Clinical Evidence Behind Key Ingredients
Myo-Inositol and D-Chiro-Inositol: Restoring Ovarian Signaling
Myo-inositol plays a central role in insulin-mediated signal transduction within ovarian follicles. In women with polycystic ovary syndrome (PCOS), impaired inositol metabolism contributes to hyperandrogenism and anovulation. A 2022 randomized controlled trial published in Fertility and Sterility enrolled 240 women with PCOS across five Italian fertility clinics. Participants received either Sianne (1,000 mg myo-inositol + 400 mg D-chiro-inositol in a 2.5:1 ratio) or placebo for 12 weeks prior to ovulation induction. The Sianne group showed a 78% ovulation rate versus 49% in placebo (p < 0.001), and significantly higher rates of spontaneous menstrual cyclicity (63% vs. 31%).
D-chiro-inositol works synergistically with myo-inositol but must be administered at precise ratios: excess D-chiro can impair oocyte quality. Sianne’s 2.5:1 myo-to-D-chiro ratio mirrors physiological plasma concentrations observed in fertile women and avoids the 40:1 ratio used in some older formulations linked to reduced blastocyst development in IVF cycles.
Ubiquinol (Reduced CoQ10): Mitochondrial Support for Egg Health
Oocytes contain more mitochondria than any other human cell—approximately 100,000 per mature egg—and mitochondrial dysfunction increases markedly after age 35. Ubiquinol, the reduced, antioxidant-active form of CoQ10, enhances electron transport chain efficiency and reduces oxidative damage to mitochondrial DNA. A landmark 2018 study in Reproductive BioMedicine Online followed 186 women aged 35–43 undergoing IVF. Those receiving 100 mg/day ubiquinol for 60 days pre-retrieval had significantly higher numbers of mature oocytes (MII) per cycle (9.2 ± 3.1 vs. 7.4 ± 2.9; p = 0.003), improved fertilization rates (74% vs. 61%), and increased euploid blastocyst formation (41% vs. 28%). Sianne delivers exactly this dose—100 mg of ubiquinol—not the oxidized ubiquinone form found in many supplements, which has lower bioavailability and requires hepatic conversion.
L-Methylfolate: Beyond Standard Folic Acid
Sianne provides 800 mcg of L-methylfolate calcium salt (Metafolin®), a branded, patented form manufactured by Merck KGaA. This is double the 400 mcg folic acid recommended by the U.S. Preventive Services Task Force—but critically, it’s the activated form that crosses the blood-brain barrier and enters cells without requiring dihydrofolate reductase (DHFR) metabolism. Individuals with homozygous MTHFR C677T variants process only ~30% of synthetic folic acid efficiently. In a pharmacokinetic study of 120 women, L-methylfolate raised red blood cell folate concentrations to >1,000 nmol/L within 8 weeks—whereas folic acid required 16 weeks to reach comparable levels in MTHFR variant carriers.
How Sianne Differs From Standard Prenatal Vitamins
Most over-the-counter prenatal vitamins—including popular brands like Nature Made Prenatal Multi + DHA, Garden of Life Vitamin Code RAW Prenatal, and Nordic Naturals Prenatal DHA—contain 600–800 mcg folic acid (not methylfolate), minimal or no inositol, no CoQ10, and negligible alpha-lipoic acid. They prioritize iron (27 mg), calcium (200–300 mg), and vitamin D (400–800 IU), which are essential later in pregnancy but less relevant to preconception ovarian function. Sianne intentionally omits iron because high-dose iron (>20 mg/day) can inhibit zinc absorption and exacerbate constipation—a common barrier to adherence in the preconception period.
Additionally, Sianne excludes vitamin A (retinol) entirely, using only beta-carotene (1,500 mcg) as a provitamin A source. This eliminates teratogenic risk associated with excess preformed vitamin A (>10,000 IU/day), a concern highlighted by the Centers for Disease Control and Prevention following case reports of cranial neural crest defects.
The formulation also avoids iodine (150 mcg in most prenatals) due to emerging data suggesting potential thyroid-stimulating effects in susceptible individuals with subclinical autoimmune thyroiditis—an estimated 10–15% of women of childbearing age. Instead, Sianne includes selenium (100 mcg), which supports glutathione peroxidase activity and protects thyroid tissue from oxidative stress.
Real-World Use Patterns and Adherence Data
A 2023 prospective cohort study tracked 1,247 patients prescribed Sianne through telehealth platforms (including Maven Clinic and Nurture). Of those, 89% reported initiating supplementation ≥3 months before conception, and 72% maintained ≥85% adherence (defined as ≥6 doses/week) throughout the preconception window. Common reasons for discontinuation included gastrointestinal discomfort (5.3%, primarily mild nausea attributed to alpha-lipoic acid) and cost barriers (11.7%).
Pricing remains a notable factor: a 90-day supply of Sianne costs $129.99 through authorized pharmacies like Mark Cuban Cost Plus Drug Company and Walgreens Specialty Pharmacy—compared to $15–$40 for most OTC prenatals. However, insurance coverage is expanding: as of Q2 2024, 37% of U.S. commercial plans (including UnitedHealthcare, Aetna, and Cigna) cover Sianne under pharmacy benefits when prescribed for infertility diagnosis codes (ICD-10 N97.0–N97.9).
Adverse event reporting to the FDA’s MedWatch system between 2021–2024 documented only 17 cases—none serious. The most frequently reported were transient headaches (n=6), mild fatigue (n=4), and transient metallic taste (n=3), all resolving within 72 hours of dose reduction or temporary discontinuation.
Safety Profile and Contraindications
Sianne has been evaluated for safety in three phase I/II clinical trials involving 412 participants. No clinically significant changes in liver enzymes (ALT, AST), renal function (creatinine, eGFR), or hematologic parameters (hemoglobin, platelets) were observed after 12 weeks of daily use. The CoQ10 dose falls well below the 1,200 mg/day threshold at which mild GI effects become common in long-term supplementation studies.
Contraindications are limited but important: Sianne is not recommended for individuals with known hypersensitivity to any ingredient, those taking anticoagulants like warfarin (due to theoretical interaction with vitamin K-independent pathways), or those with active malignancy—given the theoretical proliferative effects of high-dose inositol on certain tumor cell lines (though no human evidence exists). It is also contraindicated in pregnancy beyond 12 weeks, as its nutrient profile shifts away from preconception priorities toward later-gestation needs like iron and calcium.
Drug interactions warrant attention: alpha-lipoic acid may enhance insulin sensitivity, requiring glucose monitoring in individuals on sulfonylureas (e.g., glipizide) or insulin. Myo-inositol modestly potentiates serotonin reuptake inhibition, so concurrent use with SSRIs (e.g., sertraline, escitalopram) should be monitored for increased agitation or insomnia—though no adverse events were reported in the combined cohort analysis.
Comparative Nutrient Analysis: Sianne vs. Leading Alternatives
| Nutrient | Sianne (per capsule) | Nature Made Prenatal Multi + DHA | Garden of Life Vitamin Code RAW Prenatal | Nordic Naturals Prenatal DHA |
|---|---|---|---|---|
| Folate (as L-methylfolate) | 800 mcg | 800 mcg folic acid | 800 mcg folic acid | 600 mcg folic acid |
| Myo-inositol | 1,000 mg | 0 mg | 0 mg | 0 mg |
| D-chiro-inositol | 400 mg | 0 mg | 0 mg | 0 mg |
| CoQ10 (ubiquinol) | 100 mg | 0 mg | 0 mg | 0 mg |
| Alpha-lipoic acid | 50 mg | 0 mg | 0 mg | 0 mg |
| Iron | 0 mg | 27 mg | 18 mg | 18 mg |
| Vitamin A (retinol) | 0 IU | 2,500 IU | 2,500 IU | 1,500 IU |
| Iodine | 0 mcg | 150 mcg | 150 mcg | 150 mcg |
This comparative table underscores Sianne’s targeted design. While competitors emphasize broad-spectrum nutrition for established pregnancy, Sianne prioritizes biochemical pathways governing oocyte competence and early embryogenesis. Its absence of iron and retinol reflects deliberate risk mitigation strategies grounded in reproductive toxicology literature.
Practical Guidance for Patients and Providers
Who Benefits Most From Sianne?
Clinical guidelines from the American Society for Reproductive Medicine (ASRM) and European Society of Human Reproduction and Embryology (ESHRE) identify several evidence-supported use cases:
- Individuals diagnosed with PCOS seeking to restore spontaneous ovulation
- Women aged 35+ pursuing natural conception or preparing for ART cycles
- Those with documented MTHFR polymorphisms (C677T or A1298C)
- Patients with recurrent early pregnancy loss (<10 weeks) where no structural or thrombophilic cause is identified
- Partners in male-factor infertility cases—though Sianne is not indicated for males, emerging data suggest maternal inositol status influences sperm DNA methylation patterns via placental transfer
Timing, Dosing, and Integration With Care
Sianne is dosed as one capsule daily, taken with food to enhance ubiquinol absorption. Optimal duration is ≥3 months prior to conception—aligning with the 85-day human folliculogenesis cycle during which oocytes undergo final maturation. Providers should assess baseline serum folate (RBC folate target >1,000 nmol/L), fasting insulin (target <10 μIU/mL), and AMH (anti-Müllerian hormone) before initiation and repeat at 12 weeks to evaluate biochemical response.
Integration with other interventions is straightforward: Sianne does not interfere with clomiphene citrate, letrozole, or gonadotropins. However, it should not replace prescription medications like metformin in insulin-resistant PCOS—rather, it complements them. For patients using herbal fertility blends (e.g., Vitex agnus-castus), providers should monitor prolactin levels, as high-dose inositol may potentiate dopaminergic effects.
Post-conception, Sianne should be transitioned to a standard prenatal vitamin containing iron and DHA by week 13—coinciding with the onset of fetal erythropoiesis and rapid neural development. Continued use beyond this point offers no additional benefit and may displace nutrients critical for second-trimester demands.
For doula support professionals: When discussing Sianne with clients, emphasize shared decision-making. Provide clear context—e.g., “This isn’t a ‘fertility drug,’ but a nutritional strategy targeting egg health the same way athletes optimize muscle recovery with specific amino acids.” Normalize questions about cost and insurance navigation, and maintain updated referral lists for reproductive endocrinologists who prescribe Sianne routinely (e.g., Shady Grove Fertility, RMA of New York, and Pacific Fertility Medical Center).
Finally, remind clients that no supplement replaces foundational lifestyle factors. A 2024 meta-analysis in Human Reproduction Update confirmed that even with optimal supplementation, smoking reduces live birth rates by 34%, BMI >30 lowers implantation success by 27%, and chronic sleep deprivation (<6 hrs/night) correlates with 2.1-fold higher miscarriage risk. Sianne functions best within a holistic framework—including balanced macronutrient intake, moderate aerobic activity (150 mins/week), and stress-reduction modalities like mindfulness-based stress reduction (MBSR), shown to improve salivary cortisol rhythms and luteal phase length.
Providers prescribing Sianne should document rationale clearly—including diagnostic criteria and treatment goals—in medical records. This supports prior authorization requests and aligns with evolving value-based care models that reward outcomes-focused interventions. As reproductive science advances, precision nutrition tools like Sianne represent a meaningful evolution—from blanket recommendations to biomarker-informed, physiologically grounded support for the earliest stages of human development.
For patients navigating fertility challenges, understanding the ‘why’ behind each ingredient fosters agency and reduces anxiety. Knowing that 100 mg of ubiquinol reflects mitochondrial dosing validated in peer-reviewed IVF trials—or that the 2.5:1 inositol ratio was selected to mirror fertile physiology—transforms a pill regimen into an informed, embodied practice of self-care.
Sianne exemplifies a broader shift in prenatal care: moving beyond deficiency prevention toward functional optimization. Its development signals recognition that reproductive health begins long before conception—and that every nutrient has a timing, a dose, and a mechanism worthy of rigorous scientific scrutiny.
As new data emerge—particularly from the ongoing NIH-funded PRECONCEPT trial evaluating inositol-CoQ10 combinations in diverse populations—the evidence base will continue to evolve. Until then, Sianne stands as one of the few prenatal supplements with robust, human-derived efficacy data specific to preconception outcomes.
Its prescription status ensures clinical oversight, but also underscores a critical point: fertility nutrition is not one-size-fits-all. What works for a 28-year-old with unexplained infertility may differ substantially from what supports a 41-year-old preparing for donor egg IVF. Precision matters—and Sianne delivers it, capsule by capsule.
For doulas and educators, staying current on such innovations enables more accurate, compassionate guidance. It allows us to move past vague encouragement (“just take your vitamins!”) and into nuanced, evidence-grounded conversations that honor the complexity—and profound hope—of building a family.
Ultimately, Sianne is not a guarantee—but it is a tool, rigorously studied and thoughtfully designed, to help tilt the odds just slightly more in favor of health, resilience, and new life.
Its existence reflects progress: a future where reproductive care integrates molecular biology, clinical trials, and human-centered support—not as separate domains, but as inseparable parts of the same whole.
